{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:21:31Z","timestamp":1740144091479,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s40259-022-00524-y","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T15:34:03Z","timestamp":1648568043000},"page":"411-419","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Features and Drug Retention of TNF Inhibitors in Older Patients with Ankylosing Spondylitis: Results from the KOBIO Registry"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2827-0884","authenticated-orcid":false,"given":"Ji-Won","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunyoung A.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2609-3367","authenticated-orcid":false,"given":"Hyoun-Ah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6156-393X","authenticated-orcid":false,"given":"Chang-Hee","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7313-0795","authenticated-orcid":false,"given":"Ju-Yang","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,29]]},"reference":[{"key":"524_CR1","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","volume":"369","author":"J Braun","year":"2007","unstructured":"Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:1379\u201390.","journal-title":"Lancet"},{"key":"524_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390:73\u201384.","journal-title":"Lancet"},{"key":"524_CR3","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/rheumatology\/ket387","volume":"53","author":"LE Dean","year":"2014","unstructured":"Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence of ankylosing spondylitis. Rheumatology. 2014;53:650\u20137.","journal-title":"Rheumatology"},{"key":"524_CR4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrrheum.2014.181","volume":"11","author":"A Van Tubergen","year":"2015","unstructured":"Van Tubergen A. The changing clinical picture and epidemiology of spondyloarthritis. Nat Rev Rheumatol. 2015;11:110.","journal-title":"Nat Rev Rheumatol"},{"key":"524_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/acr.21821","volume":"65","author":"MM Ward","year":"2013","unstructured":"Ward MM, Learch TJ, Gensler LS, Davis JC Jr, Reveille JD, Weisman MH. Regional radiographic damage and functional limitations in patients with ankylosing spondylitis: differences in early and late disease. Arthritis Care Res (Hoboken). 2013;65:257\u201365.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"524_CR6","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1136\/annrheumdis-2015-207688","volume":"75","author":"S Exarchou","year":"2016","unstructured":"Exarchou S, Lie E, Lindstr\u00f6m U, Askling J, Forsblad-d\u2019Elia H, Turesson C, et al. Mortality in ankylosing spondylitis: results from a nationwide population-based study. Ann Rheum Dis. 2016;75:1466\u201372.","journal-title":"Ann Rheum Dis"},{"key":"524_CR7","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1056\/NEJMra1406182","volume":"374","author":"JD Taurog","year":"2016","unstructured":"Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016;374:2563\u201374.","journal-title":"N Engl J Med"},{"key":"524_CR8","doi-asserted-by":"publisher","first-page":"e0196281","DOI":"10.1371\/journal.pone.0196281","volume":"13","author":"MJ Carbo","year":"2018","unstructured":"Carbo MJ, Spoorenberg A, Maas F, Brouwer E, Bos R, Bootsma H, et al. Ankylosing spondylitis disease activity score is related to NSAID use, especially in patients treated with TNF-\u03b1 inhibitors. PLoS\u00a0One. 2018;13:e0196281.","journal-title":"PLoS\u00a0One"},{"key":"524_CR9","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1517\/14712598.2013.839653","volume":"13","author":"D Poddubnyy","year":"2013","unstructured":"Poddubnyy D, Rudwaleit M. Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis\u2013a five-year update. Expert Opin Biol Ther. 2013;13:1599\u2013611.","journal-title":"Expert Opin Biol Ther"},{"key":"524_CR10","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/ard.2007.078139","volume":"67","author":"JC Davis","year":"2008","unstructured":"Davis JC, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis. 2008;67:346\u201352.","journal-title":"Ann Rheum Dis"},{"key":"524_CR11","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1136\/ard.2007.075879","volume":"67","author":"J Braun","year":"2008","unstructured":"Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor \u03b1 therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis. 2008;67:340\u20135.","journal-title":"Ann Rheum Dis"},{"key":"524_CR12","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1136\/ard.62.9.817","volume":"62","author":"J Braun","year":"2003","unstructured":"Braun J, Pham T, Sieper J, Davis J, Van der Linden S, Dougados M, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2003;62:817\u201324.","journal-title":"Ann Rheum Dis"},{"key":"524_CR13","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/jcph.1348","volume":"59","author":"J Wro\u0144ski","year":"2019","unstructured":"Wro\u0144ski J, Fiedor P. The safety profile of tumor necrosis factor inhibitors in ankylosing spondylitis: are TNF inhibitors safer than we thought? J Clin Pharm. 2019;59:445\u201362.","journal-title":"J Clin Pharm"},{"key":"524_CR14","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.3899\/jrheum.141128","volume":"42","author":"C Plasencia","year":"2015","unstructured":"Plasencia C, Kneepkens EL, Wolbink G, Krieckaert CL, Turk S, Navarro-Comp\u00e1n V, et al. Comparing tapering strategy to standard dosing regimen of tumor necrosis factor inhibitors in patients with spondyloarthritis in low disease activity. J Rheumatol. 2015;42:1638\u201346.","journal-title":"J Rheumatol"},{"key":"524_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","volume":"15","author":"S Minozzi","year":"2016","unstructured":"Minozzi S, Bonovas S, Lytras T, Pecoraro V, Gonz\u00e1lez-Lorenzo M, Bastiampillai AJ, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016;15:11\u201334.","journal-title":"Expert Opin Drug Saf"},{"key":"524_CR16","doi-asserted-by":"publisher","first-page":"e0122693","DOI":"10.1371\/journal.pone.0122693","volume":"10","author":"F Maas","year":"2015","unstructured":"Maas F, Spoorenberg A, Brouwer E, Bos R, Efde M, Chaudhry RN, et al. Spinal radiographic progression in patients with ankylosing spondylitis treated with TNF-\u03b1 blocking therapy: a prospective longitudinal observational cohort study. PLoS\u00a0One. 2015;10:e0122693.","journal-title":"PLoS\u00a0One"},{"key":"524_CR17","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.3899\/jrheum.111082","volume":"39","author":"C Montilla","year":"2012","unstructured":"Montilla C, Del Pino-Montes J, Collantes-Estevez E, Font P, Zarco P, Mulero J, et al. Clinical features of late-onset ankylosing spondylitis: comparison with early-onset disease. J Rheumatol. 2012;39:1008\u201312.","journal-title":"J Rheumatol"},{"key":"524_CR18","doi-asserted-by":"publisher","first-page":"e0205651","DOI":"10.1371\/journal.pone.0205651","volume":"13","author":"SM Jung","year":"2018","unstructured":"Jung SM, Kwok S-K, Ju JH, Lee S-W, Song JJ, Yoon C-H, et al. Risk factors associated with inadequate control of disease activity in elderly patients with rheumatoid arthritis: results from a nationwide KOrean College of Rheumatology BIOlogics (KOBIO) registry. PLoS\u00a0One. 2018;13:e0205651.","journal-title":"PLoS\u00a0One"},{"key":"524_CR19","doi-asserted-by":"publisher","first-page":"176","DOI":"10.4078\/jrd.2021.28.4.176","volume":"28","author":"J Kim","year":"2021","unstructured":"Kim J, Koh JH, Choi SJ, Jeon CH, Kwok SK, Kim SK, et al. KOBIO, the first web-based Korean biologics registry operated with a unified platform among distinct disease entities. J Rheum Dis. 2021;28:176\u201382.","journal-title":"J Rheum Dis"},{"key":"524_CR20","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"SVD Linden","year":"1984","unstructured":"Linden SVD, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361\u20138.","journal-title":"Arthritis Rheum"},{"key":"524_CR21","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286\u201391.","journal-title":"J Rheumatol"},{"key":"524_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/ard.2008.094870","volume":"68","author":"C Lukas","year":"2009","unstructured":"Lukas C, Landew\u00e9 R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:18\u201324.","journal-title":"Ann Rheum Dis"},{"key":"524_CR23","first-page":"2281","volume":"21","author":"A Calin","year":"1994","unstructured":"Calin A, Garrett S, Whitelock H, Kennedy LG, O\u2019hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21:2281\u20135.","journal-title":"J Rheumatol"},{"key":"524_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/rheumatology\/30.1.69","volume":"30","author":"A Calin","year":"1991","unstructured":"Calin A, Elswood J, Edmunds L. Late onset ankylosing spondylitis\u2013a distinct disorder? Br J Rheumatol. 1991;30:69\u201370.","journal-title":"Br J Rheumatol"},{"key":"524_CR25","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3899\/jrheum.180538","volume":"46","author":"MH Derakhshan","year":"2019","unstructured":"Derakhshan MH, Goodson NJ, Packham JC, Sengupta R, Molto A, Marzo-Ortega H, et al. Increased risk of hypertension associated with spondyloarthritis disease duration: results from the ASAS-COMOSPA study. J Rheumatol. 2019;46:701\u20139.","journal-title":"J Rheumatol"},{"key":"524_CR26","doi-asserted-by":"publisher","first-page":"409","DOI":"10.7326\/M14-2470","volume":"163","author":"NN Haroon","year":"2015","unstructured":"Haroon NN, Paterson JM, Li P, Inman RD, Haroon N. Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. Ann Intern Med. 2015;163:409\u201316.","journal-title":"Ann Intern Med"},{"key":"524_CR27","doi-asserted-by":"crossref","unstructured":"Siao WZ, Liu CH, Wang YH, Wei JC, Jong GP. Increased risk of valvular heart disease in patients with ankylosing spondylitis: a nationwide population-based longitudinal cohort study. Adv Musculoskelet Dis. 2021;13:1759720x211021676.","DOI":"10.1177\/1759720X211021676"},{"key":"524_CR28","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.3346\/jkms.2014.29.9.1205","volume":"29","author":"JH Kang","year":"2014","unstructured":"Kang JH, Park DJ, Lee JW, Lee KE, Wen L, Kim TJ, et al. Drug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis. J Korean Med Sci. 2014;29:1205\u201311.","journal-title":"J Korean Med Sci"},{"key":"524_CR29","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3109\/03009742.2014.918173","volume":"43","author":"A Gulfe","year":"2014","unstructured":"Gulfe A, Kapetanovic MC, Kristensen LE. Efficacy and drug survival of anti-tumour necrosis factor-alpha therapies in patients with non-radiographic axial spondyloarthritis: an observational cohort study from Southern Sweden. Scand J Rheumatol. 2014;43:493\u20137.","journal-title":"Scand J Rheumatol"},{"key":"524_CR30","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1136\/ard.2009.124446","volume":"69","author":"B Glintborg","year":"2010","unstructured":"Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years\u2019 surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis. 2010;69:2002\u20138.","journal-title":"Ann Rheum Dis"},{"key":"524_CR31","first-page":"2078","volume":"34","author":"M Luc","year":"2007","unstructured":"Luc M, Gossec L, Ruyssen-Witrand A, Salliot C, Duclos M, Guignard S, et al. C-reactive protein predicts tumor necrosis factor-alpha blocker retention rate in axial ankylosing spondylitis. J Rheumatol. 2007;34:2078\u201381.","journal-title":"J Rheumatol"},{"key":"524_CR32","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/acr.23090","volume":"69","author":"EG Favalli","year":"2017","unstructured":"Favalli EG, Selmi C, Becciolini A, Biggioggero M, Ariani A, Santilli D, et al. Eight-year retention rate of first-line tumor necrosis factor inhibitors in spondyloarthritis: a multicenter retrospective analysis. Arthritis Care Res (Hoboken). 2017;69:867\u201374.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"524_CR33","doi-asserted-by":"publisher","first-page":"689609","DOI":"10.3389\/fmed.2021.689609","volume":"8","author":"HA Kim","year":"2021","unstructured":"Kim HA, Lee SK, Oh S, Park EH, Park YB, Shin K. Comparison of retention rates between tumor necrosis factor-\u03b1 inhibitors in patients with ankylosing spondylitis: data from the Korean College of Rheumatology Biologics Registry. Front Med. 2021;8:689609.","journal-title":"Front Med"},{"key":"524_CR34","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3899\/jrheum.201551","volume":"49","author":"H Griffiths","year":"2022","unstructured":"Griffiths H, Smith T, Mack C, Leadbetter J, Butcher B, Acar M, et al. Persistence to biologic therapy among patients with ankylosing spondylitis: an observational study using the OPAL dataset. J Rheumatol. 2022;49:150\u20136.","journal-title":"J Rheumatol"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00524-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-022-00524-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00524-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T06:04:33Z","timestamp":1653804273000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-022-00524-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,29]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["524"],"URL":"https:\/\/doi.org\/10.1007\/s40259-022-00524-y","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"type":"print","value":"1173-8804"},{"type":"electronic","value":"1179-190X"}],"subject":[],"published":{"date-parts":[[2022,3,29]]},"assertion":[{"value":"27 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by the new faculty research fund of Ajou University School of Medicine and a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, Republic of Korea (Grant number: HI16C0992).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ji-Won Kim, Eunyoung A Lee, Hyoun-Ah Kim, Chang-Hee Suh and Ju-Yang Jung have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research complied with the Helsinki Declaration. Informed consent was obtained from all enrolled participants. The same informed consent form and study protocol were provided to the independent institutional review boards\/ethics committees (IRB\/EC) at each medical centre, and each IRB\/EC reviewed the appropriateness of the protocol, risks, and benefits to the study participants. Ultimately, the IRB\/EC independently approved this study without revision of the informed consent form or study protocol.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All study participants provided informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data cannot be shared publicly because the Korean College of Rheumatology owns the data. Data are available from the Clinical Research Committee of KOBIO registry under the Korean College of Rheumatology for researchers who meet the criteria for access to confidential data. To request data, please contact Kichul Shin, MD, PhD Director, Korean College of Rheumatology Biologics Registry Associate Professor, Division of Rheumatology Director of Logistics Planning SMG-SNU Boramae Medical Center 20 Boramae-ro-5-gil, Dongjak-gu Seoul, 07061, Korea Tel 822 870 3204 Fax 822 870 3866, Email\u00a0kideb1@snu.ac.kr","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"JWK contributed to the study design and assessment plan, manuscript conceptualization and development, and critically revised the manuscript. EL contributed to method development and testing and the data analysis and interpretation. HAK and CHS contributed to the study design and assessment plan and to manuscript development. JYJ contributed to the study design and assessment plan; data acquisition, analysis, and interpretation; and manuscript conceptualization, development, and writing. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}